Xenon Pharmaceuticals (XENE)
(Delayed Data from NSDQ)
$40.15 USD
-0.64 (-1.57%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $39.00 -1.15 (-2.86%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
XENE 40.15 -0.64(-1.57%)
Will XENE be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for XENE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for XENE
Praxis Stock Up as Epilepsy Candidate Shows Reduction in Seizures
Xenon (XENE) Focuses on Neuro Candidate Amid Pipeline Woe
XENE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Xenon (XENE) Q2 Earnings Miss, Pipeline in Focus, Stock Down
Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag
Xenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus
Other News for XENE
Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress
RBC Capital Sticks to Its Buy Rating for Xenon (XENE)
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Prothena (PRTA) and Xenon (XENE)
Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Nuvalent (NUVL) and Dianthus Therapeutics (DNTH)
Xenon Pharmaceuticals Appoints New COO